http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2176253-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dee3727dba91e4e7aa3b26ce9efbcc21
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
filingDate 2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2011-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0475d35fec749192c895f17e3b354b35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c09862dfc19558de369fe468ceede3b9
publicationDate 2011-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2176253-B1
titleOfInvention A process for the preparation or purification of olmesartan medoxomil or olmesartan medoxomil hydrohalide salt
abstract The present invention relates to a process for the preparation and purification of olmesartan medoxomil hydrohalide salts and optionally converting them to olmesartan medoxomil. The invention also relates to products obtainable by the process of the invention, to pharmaceutical compositions comprising the products and to their use in medicine, particularly to treat hypertension.
priorityDate 2007-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129026427
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10562026
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865088
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7915
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128564814
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227243350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135822847
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467823910
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471807
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467400219
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9855518
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412174
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID172198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID78926
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID130881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129826180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11918
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135860904
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136046515
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394001
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393663
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136222659
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396277
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406587
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67519
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135896886
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID158781
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393972
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID98527
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128296525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6457
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57074828
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393732
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394073
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10053461

Total number of triples: 55.